Developer docs
API playgroundTry for free, no card

Search company profiles

Paracrine Therapeutics

Full company profile

uuid003etrz

Namestring
Paracrine Therapeutics
Legal namestring
Paracrine Therapeutics Pte. Ltd.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Paracrine Therapeutics Pte. Ltd. is a Singapore-based, privately held clinical-stage biotechnology company founded in 2015. The company develops mesenchymal stromal cell (MSC)-derived exosome therapeutics, positioning cell-free extracellular vesicles as a delivery mechanism for regenerative and anti-inflammatory biologic activity across multiple disease areas. Its lead clinical programme is a topical MSC exosome ointment for psoriasis, which has completed a Phase 1 safety and tolerability trial in Singapore; the broader pipeline spans osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative disorders, and radiation injury.

The core platform combines proprietary cell engineering, exosome manufacturing, and lyophilisation technologies. An immortalised MSC line provides a stable and renewable source for exosome production, and the company's lyophilisation process converts exosomes into a dry formulation to preserve biological activity and enable long-term storage and distribution. The technology is supported by a substantial intellectual property estate: Research Director Dr. Lim Sai Kiang, a Clarivate Highly Cited Researcher (2021–2024), holds over 100 granted patents covering MSC-derived extracellular vesicles as cell-free therapeutics.

The company's business model is preclinical and clinical development rather than commercial revenue generation. No products have reached approval, no revenue has been disclosed, and pricing has not been set. Go-to-market activity is presently limited to clinical trial operations in Singapore, scientific publications, and stated strategic collaborations with academic institutions, clinicians, and global pharmaceutical partners. Distribution will ultimately flow through pharmaceutical channels upon regulatory approval. Leadership includes CEO Stephen Lim (30+ years across healthcare, biotech, and SGX-listed companies) and Executive Director Ms Liu Ye (former Monetary Authority of Singapore and Singapore banking), with a Scientific Advisory Board drawn from A*STAR's Bioprocessing Technology Institute and a manufacturing consultant with biopharmaceutical industry experience.

Short descriptiontext

Paracrine Therapeutics is a Singapore-based, clinical-stage biotechnology company founded in 2015 developing MSC-derived exosome therapeutics for psoriasis, ophthalmology, orthopedics, cardiovascular, and neurodegenerative indications. Its lead programme has completed Phase 1.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHougang, Singapore
HQ citystring
Hougang
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
exosome therapeutics, regenerative medicine, cell-free therapy, MSC biotechnology, lyophilised biologics
Industry2 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Biologics
Social media profiles3 records
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Paracrine Therapeutics develops MSC-derived exosome therapeutics as cell-free regenerative biologics, combining proprietary cell engineering, exosome manufacturing, and lyophilisation technologies into a unified platform. Its lead clinical asset is a topical MSC exosome ointment for psoriasis (Phase 1 completed in Singapore), with a broader pipeline targeting osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative diseases, and radiation injury. The lyophilisation process converts exosomes into a stable dry formulation for improved storage, transportation, and clinical translation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 1 clinical trial completed demonstrating safety and tolerability of MSC exosome ointment for psoriasis treatment
+1 more record
Product overview1 text field

Paracrine Therapeutics is a clinical-stage biotechnology company offering a unified platform of MSC-derived exosome therapeutics. The core product is the PT Exosome Platform, which combines proprietary exosome technology with lyophilisation technology for stable formulations. The lead clinical programme is MSC Exosome Ointment for psoriasis (Phase 1 completed). The therapeutic pipeline spans multiple disease areas including osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative disorders, and radiation injury. The lyophilisation module enables enhanced stability and extended shelf life for the exosome therapeutics.

Product and service8 records
1MSC Exosome Ointment (Topical Exosome Therapy)
CategoryCell-free Exosome Therapeutic (Dermatology)
Description

Lead clinical-stage topical exosome ointment candidate for the treatment of psoriasis; Phase 1 safety and tolerability trial completed in Singapore. Intended as a cell-free regenerative therapeutic for inflammatory skin disease.

2PT Exosome Platform
CategoryCell-free Exosome Therapeutic Platform
Description

MSC-derived exosome therapeutics platform delivering cell-free regenerative biologics for inflammatory diseases, ophthalmology, orthopedics, and neurodegenerative disorders. Designed for consistent, scalable, and clinically translatable exosome production.

3Lyophilisation Technology
CategoryBiologics Formulation & Manufacturing Technology
Description

Proprietary freeze-drying process that stabilises MSC-derived exosomes while preserving their biological activity. Converts exosomes into a dry formulation to improve product stability, long-term storage, and distribution logistics for therapeutic use.

4Osteochondral Repair Programme
CategoryCell-free Exosome Therapeutic (Orthopaedics)
Description

Pipeline therapeutic programme applying MSC-derived exosome therapeutics to support osteochondral (cartilage and bone) tissue repair in orthopaedic indications.

5Corneal Scarring and Ocular Surface Disease Programme
CategoryCell-free Exosome Therapeutic (Ophthalmology)
Description

Pipeline therapeutic programme applying MSC-derived exosome therapeutics to treat corneal scarring and other ocular surface diseases in ophthalmology.

6Cardiovascular Repair Programme
CategoryCell-free Exosome Therapeutic (Cardiovascular)
Description

Pipeline therapeutic programme applying MSC-derived exosome therapeutics to support cardiovascular repair and regenerative treatment of heart disease.

7Neurodegenerative Disease Programme
CategoryCell-free Exosome Therapeutic (Neurology)
Description

Pipeline therapeutic programme applying MSC-derived exosome therapeutics to neurodegenerative disorders where tissue repair and modulation of inflammatory pathways are clinically relevant.

8Radiation Injury Research Programme
CategoryCell-free Exosome Therapeutic (Radiation Injury)
Description

Research programme investigating the use of MSC extracellular vesicles (exosomes) to mitigate the effects of radiation injury on tissues.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Academic Institutions
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaborations with leading academic institutions for research and development of exosome therapeutics, translating scientific discoveries into clinical applications

paracrinetherapeutics.com
2Clinicians
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborations with clinicians to advance clinical programmes and support therapeutic development through clinical expertise and patient access

paracrinetherapeutics.com
3Global Pharmaceutical Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaborations with global pharmaceutical companies for development and potential commercialisation of exosome therapeutics worldwide

paracrinetherapeutics.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Provider of MSC and stem cell research tools, reagents, and culture systems. Included as an adjacent/ecosystem participant because it supplies enabling technologies used across the MSC and exosome therapeutic field, including by Paracrine's pipeline customers and academic collaborators.

2Pluristem Therapeutics
TypeBroad incumbent
Description

Clinical-stage cell therapy company using placenta-derived mesenchymal-like cells for inflammatory, muscle, and haematological indications. Broad incumbent because both companies operate in regenerative/cell-based therapeutics for chronic inflammatory and degenerative conditions.

3Codiak BioSciences
TypeEmerging player
Description

Pioneering engineered exosome therapeutics company (engEx platform) that advanced multiple programmes into the clinic before restructuring. Emerging player due to high technology overlap in MSC-derived/exposome therapeutics despite its reduced operational footprint.

TypeEmerging player
Description

South Korea-based clinical-stage company developing MSC-derived exosome therapeutics for atopic dermatitis, alopecia, and regenerative applications. Emerging player because it competes in overlapping dermatology and regenerative indications with a similar MSC-exosome modality.

TypeBroad incumbent
Description

Commercial-stage allogeneic MSC-based cell therapy company with approved product Ryoncil and late-stage programmes in inflammatory and cardiovascular indications. Broad incumbent because Mesoblast uses the same MSC biological source as Paracrine, but delivers living cells rather than exosomes.

TypeDirect peer
Description

UK-based clinical-stage biotech engineering exosome-based therapeutics for rare diseases. Direct peer because both companies develop engineered/cell-derived extracellular vesicle therapeutics using similar biological chassis and face the same regulatory, manufacturing, and clinical translation challenges.

TypeDirect peer
Description

Clinical-stage US biotech developing bone marrow-derived MSC extracellular vesicle (ExoFlo) therapeutics for inflammatory conditions, wound healing, and orthopedics. Direct peer due to near-identical MSC-derived exosome modality and overlapping indication focus.

TypeDirect peer
Description

Clinical-stage biotech developing cell-derived and exosome-based therapeutics, notably CAP-1002 (cardiac cell therapy) and exosome programmes for inflammatory and rare indications. Direct peer due to overlapping cell-derived therapeutic modality and pipeline overlap in regenerative applications.

TypeEmerging player
Description

Mayo Clinic spin-out developing platelet-derived and MSC-derived extracellular vesicle therapeutics for wound healing, orthopedics, and inflammatory conditions. Emerging player because it competes in overlapping indication areas (e.g., orthopedics) using a closely related extracellular vesicle modality.

TypeBroad incumbent
Description

Japanese cell therapy company developing MultiStem (multipotent adult progenitor cell) therapies for stroke, ARDS, and inflammatory indications. Broad incumbent due to overlap in regenerative medicine target indications and biological approach using stem-cell derived therapeutics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Paracrine Therapeutics

Regenerative Medicine Biologicsparacrinetherapeutics.com

Paracrine Therapeutics is a Singapore-based, clinical-stage biotechnology company founded in 2015 developing MSC-derived exosome therapeutics for psoriasis, ophthalmology, orthopedics, cardiovascular, and neurodegenerative indications. Its lead programme has completed Phase 1.

What Paracrine Therapeutics does

Paracrine Therapeutics Pte. Ltd. is a Singapore-based, privately held clinical-stage biotechnology company founded in 2015. The company develops mesenchymal stromal cell (MSC)-derived exosome therapeutics, positioning cell-free extracellular vesicles as a delivery mechanism for regenerative and anti-inflammatory biologic activity across multiple disease areas. Its lead clinical programme is a topical MSC exosome ointment for psoriasis, which has completed a Phase 1 safety and tolerability trial in Singapore; the broader pipeline spans osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative disorders, and radiation injury.

The core platform combines proprietary cell engineering, exosome manufacturing, and lyophilisation technologies. An immortalised MSC line provides a stable and renewable source for exosome production, and the company's lyophilisation process converts exosomes into a dry formulation to preserve biological activity and enable long-term storage and distribution. The technology is supported by a substantial intellectual property estate: Research Director Dr. Lim Sai Kiang, a Clarivate Highly Cited Researcher (2021–2024), holds over 100 granted patents covering MSC-derived extracellular vesicles as cell-free therapeutics.

The company's business model is preclinical and clinical development rather than commercial revenue generation. No products have reached approval, no revenue has been disclosed, and pricing has not been set. Go-to-market activity is presently limited to clinical trial operations in Singapore, scientific publications, and stated strategic collaborations with academic institutions, clinicians, and global pharmaceutical partners. Distribution will ultimately flow through pharmaceutical channels upon regulatory approval. Leadership includes CEO Stephen Lim (30+ years across healthcare, biotech, and SGX-listed companies) and Executive Director Ms Liu Ye (former Monetary Authority of Singapore and Singapore banking), with a Scientific Advisory Board drawn from A*STAR's Bioprocessing Technology Institute and a manufacturing consultant with biopharmaceutical industry experience.

Paracrine Therapeutics firmographics

Firmographics
Name
Paracrine Therapeutics
Legal name
Paracrine Therapeutics Pte. Ltd.
Website
https://paracrinetherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Paracrine Therapeutics is a Singapore-based, clinical-stage biotechnology company founded in 2015 developing MSC-derived exosome therapeutics for psoriasis, ophthalmology, orthopedics, cardiovascular, and neurodegenerative indications. Its lead programme has completed Phase 1.
Ownership category
akta.pro rank

Paracrine Therapeutics industry classification

Industry
Product category
Regenerative Medicine Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Exosome therapeutics
  • Regenerative medicine
  • Cell-free therapy
  • MSC biotechnology
  • Lyophilised biologics

Where Paracrine Therapeutics is headquartered

Location

Headquarters

HQ city
Hougang
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

Paracrine Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels5 records

Paracrine Therapeutics product offering

Product offering

Core offering

Paracrine Therapeutics develops MSC-derived exosome therapeutics as cell-free regenerative biologics, combining proprietary cell engineering, exosome manufacturing, and lyophilisation technologies into a unified platform. Its lead clinical asset is a topical MSC exosome ointment for psoriasis (Phase 1 completed in Singapore), with a broader pipeline targeting osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative diseases, and radiation injury. The lyophilisation process converts exosomes into a stable dry formulation for improved storage, transportation, and clinical translation.

Product overview

Paracrine Therapeutics is a clinical-stage biotechnology company offering a unified platform of MSC-derived exosome therapeutics. The core product is the PT Exosome Platform, which combines proprietary exosome technology with lyophilisation technology for stable formulations. The lead clinical programme is MSC Exosome Ointment for psoriasis (Phase 1 completed). The therapeutic pipeline spans multiple disease areas including osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative disorders, and radiation injury. The lyophilisation module enables enhanced stability and extended shelf life for the exosome therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • MSC Exosome Ointment (Topical Exosome Therapy) Lead clinical-stage topical exosome ointment candidate for the treatment of psoriasis; Phase 1 safety and tolerability trial completed in Singapore. Intended as a cell-free regenerative therapeutic for inflammatory skin disease.
  • PT Exosome Platform MSC-derived exosome therapeutics platform delivering cell-free regenerative biologics for inflammatory diseases, ophthalmology, orthopedics, and neurodegenerative disorders. Designed for consistent, scalable, and clinically translatable exosome production.
  • Lyophilisation Technology Proprietary freeze-drying process that stabilises MSC-derived exosomes while preserving their biological activity. Converts exosomes into a dry formulation to improve product stability, long-term storage, and distribution logistics for therapeutic use.
  • Osteochondral Repair Programme Pipeline therapeutic programme applying MSC-derived exosome therapeutics to support osteochondral (cartilage and bone) tissue repair in orthopaedic indications.
  • Corneal Scarring and Ocular Surface Disease Programme Pipeline therapeutic programme applying MSC-derived exosome therapeutics to treat corneal scarring and other ocular surface diseases in ophthalmology.
  • Cardiovascular Repair Programme Pipeline therapeutic programme applying MSC-derived exosome therapeutics to support cardiovascular repair and regenerative treatment of heart disease.
  • Neurodegenerative Disease Programme Pipeline therapeutic programme applying MSC-derived exosome therapeutics to neurodegenerative disorders where tissue repair and modulation of inflammatory pathways are clinically relevant.
  • Radiation Injury Research Programme Research programme investigating the use of MSC extracellular vesicles (exosomes) to mitigate the effects of radiation injury on tissues.

Quantifiable outcome

  • Phase 1 clinical trial completed demonstrating safety and tolerability of MSC exosome ointment for psoriasis treatment
  • +1 more outcomes

Companies that use Paracrine Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Paracrine Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Paracrine Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Academic InstitutionscoreStrategic or Co-development PartnerStrategic collaborations with leading academic institutions for research and development of exosome therapeutics, translating scientific discoveries into clinical applications
  • ClinicianscoreStrategic or Co-development PartnerCollaborations with clinicians to advance clinical programmes and support therapeutic development through clinical expertise and patient access
  • Global Pharmaceutical PartnerscoreStrategic or Co-development PartnerStrategic collaborations with global pharmaceutical companies for development and potential commercialisation of exosome therapeutics worldwide

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Paracrine Therapeutics competitors and assessment

Company assessment

Others

  • Stemcell Technologies: Provider of MSC and stem cell research tools, reagents, and culture systems. Included as an adjacent/ecosystem participant because it supplies enabling technologies used across the MSC and exosome therapeutic field, including by Paracrine's pipeline customers and academic collaborators.

Broad incumbents

  • Pluristem Therapeutics: Clinical-stage cell therapy company using placenta-derived mesenchymal-like cells for inflammatory, muscle, and haematological indications. Broad incumbent because both companies operate in regenerative/cell-based therapeutics for chronic inflammatory and degenerative conditions.
  • Mesoblast: Commercial-stage allogeneic MSC-based cell therapy company with approved product Ryoncil and late-stage programmes in inflammatory and cardiovascular indications. Broad incumbent because Mesoblast uses the same MSC biological source as Paracrine, but delivers living cells rather than exosomes.
  • Healios K.K. (formerly Athersys): Japanese cell therapy company developing MultiStem (multipotent adult progenitor cell) therapies for stroke, ARDS, and inflammatory indications. Broad incumbent due to overlap in regenerative medicine target indications and biological approach using stem-cell derived therapeutics.

Emerging players

  • Codiak BioSciences: Pioneering engineered exosome therapeutics company (engEx platform) that advanced multiple programmes into the clinic before restructuring. Emerging player due to high technology overlap in MSC-derived/exposome therapeutics despite its reduced operational footprint.
  • ExoCoBio: South Korea-based clinical-stage company developing MSC-derived exosome therapeutics for atopic dermatitis, alopecia, and regenerative applications. Emerging player because it competes in overlapping dermatology and regenerative indications with a similar MSC-exosome modality.
  • Rion LLC: Mayo Clinic spin-out developing platelet-derived and MSC-derived extracellular vesicle therapeutics for wound healing, orthopedics, and inflammatory conditions. Emerging player because it competes in overlapping indication areas (e.g., orthopedics) using a closely related extracellular vesicle modality.

Direct peers

  • Evox Therapeutics: UK-based clinical-stage biotech engineering exosome-based therapeutics for rare diseases. Direct peer because both companies develop engineered/cell-derived extracellular vesicle therapeutics using similar biological chassis and face the same regulatory, manufacturing, and clinical translation challenges.
  • Direct Biologics: Clinical-stage US biotech developing bone marrow-derived MSC extracellular vesicle (ExoFlo) therapeutics for inflammatory conditions, wound healing, and orthopedics. Direct peer due to near-identical MSC-derived exosome modality and overlapping indication focus.
  • Capricor Therapeutics: Clinical-stage biotech developing cell-derived and exosome-based therapeutics, notably CAP-1002 (cardiac cell therapy) and exosome programmes for inflammatory and rare indications. Direct peer due to overlapping cell-derived therapeutic modality and pipeline overlap in regenerative applications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Paracrine Therapeutics social profiles

Digital presence

Paracrine Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Paracrine Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Paracrine Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Paracrine Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paracrine Therapeutics

What does Paracrine Therapeutics do?

Paracrine Therapeutics develops MSC-derived exosome therapeutics as cell-free regenerative biologics, combining proprietary cell engineering, exosome manufacturing, and lyophilisation technologies into a unified platform. Its lead clinical asset is a topical MSC exosome ointment for psoriasis (Phase 1 completed in Singapore), with a broader pipeline targeting osteochondral repair, corneal scarring and ocular surface diseases, cardiovascular repair, neurodegenerative diseases, and radiation injury. The lyophilisation process converts exosomes into a stable dry formulation for improved storage, transportation, and clinical translation.

Is Paracrine Therapeutics a public or private company?

Paracrine Therapeutics is a private company. It is classified as unknown and is currently operating.

When was Paracrine Therapeutics founded?

Paracrine Therapeutics was founded in 2015. It employs 1 to 10 people.

Where is Paracrine Therapeutics based?

Paracrine Therapeutics is headquartered in Hougang, Singapore, in the Asia region.

Who are Paracrine Therapeutics's main competitors?

Stemcell Technologies is listed as an others. Broad incumbents are Pluristem Therapeutics, Mesoblast and Healios K.K. (formerly Athersys). Emerging players are Codiak BioSciences, ExoCoBio and Rion LLC. Direct peers are Evox Therapeutics, Direct Biologics and Capricor Therapeutics.

Does Paracrine Therapeutics have an API?

No public API is recorded for Paracrine Therapeutics.

What industry is Paracrine Therapeutics in?

Paracrine Therapeutics's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales